---
title: "Jeena Sikho Lifecare Ltd (JSLL) — Share Price, Financials & Analysis"
symbol: "JSLL"
company: "Jeena Sikho Lifecare Ltd"
canonical: "https://tapetide.com/stocks/JSLL"
isin: "INE0J5801029"
nse_symbol: "JSLL"
bse_code: "544476"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 6328.77
generated_at: "2026-09-13T18:56:01.655Z"
---

# Jeena Sikho Lifecare Ltd (JSLL)

Canonical page: https://tapetide.com/stocks/JSLL

## Company

- **NSE Symbol:** JSLL
- **BSE Code:** 544476
- **ISIN:** INE0J5801029
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Consumer Discretionary
- **Stock Type:** EQUITY
- **Listed Since:** 2025-08-11
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** jeenasikho.com

## About

Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.

## Latest Price

- **Price:** ₹511.85
- **Change:** -6.45 (-1.24%)
- **Open:** ₹516
- **Day High:** ₹516.7
- **Day Low:** ₹507
- **Previous Close:** ₹518.3
- **Volume:** 342560
- **As Of:** 2026-09-11T10:25:13+00:00

## Key Fundamentals

Observed at 2026-09-11T04:37:44.030149Z.

- **Market Cap:** ₹6328.77 Cr
- **Classification:** Microcap
- **P/E (reported):** 27.2
- **P/E (TTM):** 26.9
- **EPS (TTM):** ₹19.03
- **Book Value:** ₹37.58
- **Price to Book:** 13.78
- **Dividend Yield:** 0.87%
- **ROE:** 26.65%
- **ROCE:** 35.59%
- **Debt to Equity:** 0.27
- **Revenue (yearly):** ₹801.36 Cr
- **Net Income:** ₹217.08 Cr
- **EBITDA:** ₹349.42 Cr
- **52-Week High:** ₹849.5
- **52-Week Low:** ₹492
- **RSI (14):** 47.87

## Tapetide Score

- **Score:** 55 / 100
- **Score date:** 2026-09-04
- **Archetype:** Out of Favour
- **What it means:** Financially sound, yet the market is not rewarding it. Cases like this usually need a specific reason the pessimism is misplaced, and patience for that reason to play out.
- **Pillar profile:** Quality: Good · Valuation: Cheap · Momentum: Falling
- **Percentile:** 70.1 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 66.72 | 9% |
| growth | 98.37 | 9% |
| momentum | 17.05 | 12% |
| ownership | 31.9 | 24% |
| quality | 78.91 | 22% |
| valuation | 62.19 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is expected to give good quarter
- Company has delivered good profit growth of 84.5% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 49.6%
- Company has been maintaining a healthy dividend payout of 19.1%
- Debtor days have improved from 51.4 to 31.8 days.

### Weaknesses

- Stock is trading at 13.6 times its book value

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -11.19% | 549.54% | -51.16% |
| ebitda margin growth | 30.87% | 85.59% | 226.89% | — |
| net income growth | 46.12% | 548% | 88% | 85% |
| revenue growth | 9% | 286.57% | 58% | 43% |
| roce | 40.09% | -17.44% | -17.44% | — |
| roe | 46.16% | -13.14% | 28.67% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 100 | 114 | 116 | 139 | 174 | 190 | 222 | 216 | 224 |
| Expenses | 75 | 74 | 86 | 93 | 96 | 98 | 121 | 138 | 132 |
| Operating Profit | 25 | 40 | 30 | 46 | 79 | 92 | 101 | 78 | 92 |
| OPM % | 25 | 35 | 26 | 33 | 45 | 48 | 45 | 36 | 41 |
| Other Income | 3 | 3 | 0 | 0 | 1 | 1 | 3 | 4 | 14 |
| Interest | 1 | 2 | 4 | 3 | 2 | 4 | 3 | 4 | 3 |
| Depreciation | 5 | 6 | 8 | 9 | 10 | 10 | 11 | 16 | 15 |
| Profit before tax | 21 | 35 | 18 | 34 | 69 | 79 | 89 | 62 | 87 |
| Tax % | 23 | 25 | 26 | 25 | 25 | 25 | 25 | 26 | 25 |
| Net Profit | 16 | 27 | 13 | 25 | 51 | 59 | 67 | 45 | 66 |
| EPS in Rs | 1.3 | 2.14 | 1.06 | 2.04 | 4.13 | 4.73 | 5.37 | 3.65 | 5.28 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 106 | 94 | 136 | 146 | 204 | 324 | 469 | 801 | 851 |
| Expenses | 95 | 84 | 119 | 128 | 158 | 231 | 344 | 452 | 488 |
| Operating Profit | 11 | 11 | 17 | 18 | 46 | 93 | 125 | 350 | 363 |
| OPM % | 10 | 11 | 13 | 12 | 23 | 29 | 27 | 44 | 43 |
| Other Income | 0 | 1 | 1 | 1 | 2 | 6 | 6 | 9 | 22 |
| Interest | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 13 | 15 |
| Depreciation | 1 | 2 | 2 | 3 | 3 | 5 | 9 | 48 | 53 |
| Profit before tax | 8 | 8 | 14 | 15 | 45 | 94 | 122 | 298 | 317 |
| Tax % | 28 | 26 | 27 | 26 | 24 | 26 | 26 | 25 | — |
| Net Profit | 6 | 6 | 10 | 11 | 34 | 69 | 91 | 222 | 237 |
| EPS in Rs | 66.67 | 63.67 | 93.55 | 1.24 | 2.71 | 5.57 | 7.3 | 17.87 | 19.03 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 8 | 17 | 15 | 25 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.1 | 0.1 | 0.1 | 10 | 14 | 25 | 25 | 25 |
| Reserves | 8 | 14 | 24 | 26 | 112 | 167 | 248 | 443 |
| Borrowings | 16 | 12 | 12 | 7 | 1 | 1 | 11 | 127 |
| Other Liabilities | 12 | 12 | 13 | 18 | 24 | 28 | 45 | 78 |
| Total Liabilities | 36 | 38 | 49 | 62 | 151 | 221 | 328 | 673 |
| Fixed Assets | 13 | 17 | 23 | 28 | 60 | 67 | 153 | 307 |
| CWIP | 0 | 0 | 0 | 5 | 1 | 4 | 13 | 2 |
| Investments | 0 | 0 | 0 | 0 | 5 | 4 | 4 | 95 |
| Other Assets | 23 | 21 | 26 | 28 | 86 | 146 | 159 | 269 |
| Total Assets | 36 | 38 | 49 | 62 | 151 | 221 | 328 | 673 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 1 | 12 | 18 | 17 | 17 | 37 | 69 | 262 |
| Cash from Investing Activity | -11 | -6 | -8 | -20 | -57 | -18 | -70 | -211 |
| Cash from Financing Activity | 7 | -5 | -2 | -5 | 48 | -3 | -1 | -59 |
| Net Cash Flow | -2 | 1 | 8 | -7 | 8 | 15 | -2 | -8 |
| Free Cash Flow | -10 | 6 | 9 | -1 | -13 | 23 | -40 | 231 |
| CFO/OP | 35 | 130 | 125 | 118 | 55 | 66 | 81 | 96 |

### Ratios

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 15 | 17 | 9 | 22 | 40 | 46 | 76 | 32 |
| Inventory Days | 204 | 315 | 208 | 136 | 87 | 121 | 135 | 80 |
| Days Payable | 125 | 168 | 73 | 109 | 129 | 75 | 111 | 86 |
| Cash Conversion Cycle | 94 | 163 | 143 | 49 | -2 | 92 | 100 | 26 |
| Working Capital Days | -16 | -15 | -19 | -11 | 29 | 58 | 55 | 54 |
| ROCE % | — | 38 | 50 | 39 | 53 | 58 | 50 | 71 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2021 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 90% | 65.89% | 66.2% | 67.91% | 67.91% | 65.84% | 63.53% | 63.53% | 63.61% | 63.62% | 63.62% | 63.62% |
| FIIs | 0% | 0% | 0% | 2% | 0% | 4.05% | 5.95% | 5.91% | 6.59% | 6.31% | 6.17% | 4.78% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.15% | 0.11% | 0.46% | 0.36% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 10% | 16.21% | 15.28% | 14.41% | 17.34% | 16.72% | 16.67% | 17.05% | 17.32% | 18.19% | 18.37% | 21.02% |
| Others | 0% | 17.9% | 18.52% | 15.68% | 14.75% | 13.39% | 13.85% | 13.5% | 12.33% | 11.76% | 11.38% | 10.22% |
| No. of Shareholders | 7 | 834 | 663 | 814 | 2721 | 3423 | 5967 | 6603 | 16362 | 22181 | 25905 | 43413 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 4 / 7 / 8

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 510.45 | Buy |
| EMA (10) | 511.73 | Buy |
| SMA (20) | 509.76 | Buy |
| EMA (20) | 516.99 | Sell |
| SMA (50) | 543.99 | Sell |
| EMA (50) | 541.38 | Sell |
| SMA (100) | 590.44 | Sell |
| EMA (100) | 573.35 | Sell |
| SMA (200) | 630.92 | Sell |
| EMA (200) | 590.62 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 45.4 | Neutral |
| MACD (12,26,9) | -9.43 | Buy |
| Stochastic (14,3,3) | 40.8 | Neutral |
| ADX (14) | 12.81 | Neutral |
| Williams %R (14) | -59.29 | Neutral |
| ATR (14) | 19.55 | High Volatility |
| ROC (12) | -0.47 | Sell |
| Stoch RSI (14) | 77.89 | Neutral |
| UO (7,14,28) | 37.24 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Intimation Regarding Postponement In Commencement Of Commercial Operations At The New Day Care Clinic In Ayodhya Uttar Pradesh](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f291892c-ad70-414d-a58d-f2579f275b5a.pdf) |
| 2026-09-09 | [Intimation Regarding Postponement In Commencement Of Commercial Operations At The New Hospital Facility In Lucknow Uttar Pradesh](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70ea0781-d61f-4a73-b276-e12bc8e2bb09.pdf) |
| 2026-09-08 | [Receipt Of NABH Accreditation For Pune Hospital](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=afec55b4-5251-4b58-839b-8854e89339f5.pdf) |
| 2026-09-05 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2af714e0-06b2-4b33-8948-e6a94ae4de46.pdf) |
| 2026-09-05 | [Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- Launch Of New Product](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85406550-1f94-4de0-b2e7-effccd13b65b.pdf) |
| 2026-09-04 | [Notice Of The 9Th Annual General Meeting And Integrated Annual Report For Financial Year 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3600582-3137-4c23-a702-a5cc3cffa9fe.pdf) |
| 2026-09-04 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac2bb0aa-fbcb-48e1-84ef-b20c273d53a1.pdf) |
| 2026-09-04 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=35f9220e-bda5-4669-9aa8-58dab0340e81.pdf) |
| 2026-09-04 | [The Aforesaid Communication Provides The Web-Link Through Which The Integrated Annual Report Of The Company For The Financial Year 2025-26 And The Notice Convening The 9Th Annual General Meeting Of The Company Can Be Accessed On The CompanyS Website](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2180a91d-7894-4817-b336-7cf0b54f79b0.pdf) |
| 2026-09-02 | [Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015-Launch Of New Products](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3fbacb11-f8c7-40b8-ae96-c8a97187ccff.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=67bc12f4-ef83-4eb1-9279-0d4c30b7664e.pdf) |
| 2026-06-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f7dab8a-7d33-48c4-81d0-f27cd40b8999.pdf) |
| 2026-02-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7fe962c2-bbd2-441b-8215-b7d4bdc44ab6.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=598340fb-eb51-4337-8ba2-cfc24b4d4956.pdf) |
| 2025-08-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0452d3e-f791-493a-bdc2-7589fb2c26ee.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ec61c55-4bdc-46e4-80fd-100900e98ebb.pdf) |
| 2026-06-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98c53b11-79d9-41ed-81d3-326aea257a6b.pdf) |
| 2026-02-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0a9ca282-0752-4a62-ad6b-da4aa36a29f9.pdf) |
| 2025-11-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21f11a23-5d34-4bb8-b1b6-88eff394c9a1.pdf) |
| 2025-08-19 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fcabb0ce-7659-471c-9967-169a7e8971cc.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-09 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9fa6211e-ac55-4e06-8c49-ad82a4ceac83.pdf) |
| 2026-06-01 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4f85b742-25ab-4de9-9bbd-420b291b68a6.pdf) |
| 2026-05-31 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c475b15d-8865-452d-a360-9b3a3cc77598.pdf) |
| 2026-02-08 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c592f8f1-eaf8-4d4d-9856-b714671fa718.pdf) |
| 2025-11-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=573135a0-2404-4f55-a5c7-aaa4f49ebdf6.pdf) |
| 2025-08-16 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=007120d2-10c9-4e4a-b555-4e6f574f9ed5.pdf) |
| 2025-08-15 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5801b3e-24ef-44c3-862a-5d22b99ca2c1.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-07 | [Outcome Of The Meeting Of The Board Of Directors Of Jeena Sikho Lifecare Limited Held On August 07 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b744e1a8-db6d-43d7-98a6-3276c8c7891e.pdf) |
| 2026-05-30 | [Declaration Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Financial Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=488e600b-e499-4b3a-ab0f-6e55dfdcf151.pdf) |
| 2026-02-07 | [Jeena Sikho Lifecare Limited Has Submitted To The Exchange The Unaudited Financial Results (Standalone And Consolidated) Along With Limited Review Report Thereon For The Quarter And Nine Months Ended December 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc2b8299-e01e-487f-91fb-946858ff782c.pdf) |
| 2025-11-06 | [Results-Financial Results For Quarter Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b6b5ea1-ad0a-408b-a518-771fae4fcbe7.pdf) |
| 2025-08-14 | [The Un-Audited Financial Results Along With Limited Review Report For Quarter Ended 30Th June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=edc1d364-c93a-4b25-acf5-eea4194ac990.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/598340fb-eb51-4337-8ba2-cfc24b4d4956.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://nsearchives.nseindia.com/corporate/JSLL_12112024145158_Investor_Presentation_JSLL.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://nsearchives.nseindia.com/corporate/JSLL_18112024192106_Transcript_Call_Final.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c475b15d-8865-452d-a360-9b3a3cc77598.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/c475b15d-8865-452d-a360-9b3a3cc77598.pdf) |
| May 2025 | [Concall - May 2025](https://nsearchives.nseindia.com/corporate/JEENASIKHO_26052025175716_Intimation_Transcript.pdf) |
| May 2024 | [Concall - May 2024](https://nsearchives.nseindia.com/corporate/JSLL_21052024191457_transcript_con_call_final.pdf) |
| Jun 2026 | [Concall - Jun 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4f85b742-25ab-4de9-9bbd-420b291b68a6.pdf) |
| Jun 2026 | [Concall - Jun 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4f85b742-25ab-4de9-9bbd-420b291b68a6.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7fe962c2-bbd2-441b-8215-b7d4bdc44ab6.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Mar - Board approved amendments to Jeena Sikho Lifecare's insider trading and fair disclosure Code on March 9, 2026. | [Amendment To The Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive Information. 9 Mar - Board approved amendments to Jeena Sikho Lifecare's insider trading and fair disclosure Code on March 9, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a1e82bbe-c6e9-4c03-947f-02e63586fb66.pdf) |
| 8 May - Board approved sale of 48 bigha land in Punjab for ₹24 crore on 8 May 2026. | [Sale Of Land - Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015. 8 May - Board approved sale of 48 bigha land in Punjab for ₹24 crore on 8 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/97ffebbb-cc59-4792-aa7e-f156d6856229.pdf) |
| 6 Mar - Jeena Sikho Lifecare Limited informs the Exchange about Schedule of Investor/Analyst meet(s). | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 6 Mar - Jeena Sikho Lifecare Limited informs the Exchange about Schedule of Investor/Analyst meet(s).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4e0aa0da-55ce-4eb8-bb20-cbb18804dd18.pdf) |
| 4 May - Seven case studies and two case reports published in JASE on Ayurvedic treatments. | [Jeena Sikho Lifecare Limited Has informed About Publication Of Case Study And Case Reports. 4 May - Seven case studies and two case reports published in JASE on Ayurvedic treatments.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6d5228bf-4402-4cb7-ba8e-02046e0c1828.pdf) |
| 4 May - Seven case studies and two case reports published in JASE on Ayurvedic treatments. | [Jeena Sikho Lifecare Limited Has informed About Publication Of Case Study And Case Reports. 4 May - Seven case studies and two case reports published in JASE on Ayurvedic treatments.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/6d5228bf-4402-4cb7-ba8e-02046e0c1828.pdf) |
| 4 May - Jeena Sikho Lifecare appoints GoIndia Advisors LLP as investor relations management agency. | [Intimation For Appointment Of Investor Relations Management Agency Of The Company 4 May - Jeena Sikho Lifecare appoints GoIndia Advisors LLP as investor relations management agency.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/626e3310-57ce-4d85-a806-15a7d0898014.pdf) |
| 4 May - Jeena Sikho Lifecare appoints GoIndia Advisors LLP as investor relations management agency. | [Intimation For Appointment Of Investor Relations Management Agency Of The Company 4 May - Jeena Sikho Lifecare appoints GoIndia Advisors LLP as investor relations management agency.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/626e3310-57ce-4d85-a806-15a7d0898014.pdf) |
| 2d - Jeena Sikho Lifecare approved sale of 48 bigha non-operational land in Patiala for ₹24 crore. | [Revised Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015, As Amended ('SEBI Listing Regulations') - Sale Of Land 2d - Jeena Sikho Lifecare approved sale of 48 bigha non-operational land in Patiala for ₹24 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/d2ca5bad-3d56-40e7-8752-e1614b6476de.pdf) |
| 23 Mar - Three Ayurvedic case studies/reports by company clinicians published in IJAR, announced 23 March 2026. | [Jeena Sikho Lifecare Limited Has informed About Publication Of Case Study And Case Reports. 23 Mar - Three Ayurvedic case studies/reports by company clinicians published in IJAR, announced 23 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5168f3d1-dac1-4389-8715-fb415744e161.pdf) |
| 23 Mar - Jeena Sikho Lifecare closes trading window from April 1, 2026 until 48 hours post-audited results. | [Closure of Trading Window 23 Mar - Jeena Sikho Lifecare closes trading window from April 1, 2026 until 48 hours post-audited results.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6d4cda6a-595c-49b2-84cd-91a2f0bb43c8.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_24802_JSLL_2023_2024_03082024175221.pdf) |
| from nse | [Annual Report 2023 from nse](https://archives.nseindia.com/annual_reports/SME_AR_22775_JSLL_2022_2023_16082023203923_08162023210000.zip) |
| from nse | [Annual Report 2022 from nse](https://archives.nseindia.com/annual_reports/SME_AR_21510_JSLL_2021_2022_06092022175907_09062022180005.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1ebf05f3-7029-42cd-be2c-419752cbf754.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:56:01.655Z.